Alvotech ALVOW
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $586.32M, +19.7% YoY · Filed Mar 31, 2026
Alvotech (ALVO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $586.3 million and net income of $27.9 million. Free cash flow was -$114.7 million. As of Dec 31, 2025 it held $172.4 million in cash and investments and $1.4 billion in total debt.
Revenue
$586.32M
+19.7% vs prior year
Net income
$27.92M
+112.0% vs prior year
Operating cash flow
$-50.20M
+78.8% vs prior year
Free cash flow
$-114.67M
+60.5% vs prior year
EPS
$0.10
+111.5% vs prior year
Dividend per share
None
Shares outstanding
312.02M
+3.4% vs prior year
Net cash
$-1.28B
FY 2025
Operating margin
13.3%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALVO (Nasdaq), ALVOW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Luxembourg
- Headquarters
- Luxembourg, Luxembourg
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1898416
- Former names
- Alvotech Lux Holdings S.A.S. (until May 2, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $586.3M | $489.7M | $91.4M | $83.0M |
| Operating income | $78.2M | $69.6M | -$354.9M | -$346.4M |
| Net income | $27.9M | -$231.9M | -$551.7M | -$513.6M |
| Diluted EPS | $0.10 | -$0.87 | -$2.43 | -$2.60 |
| Operating cash flow | -$50.2M | -$236.8M | -$312.2M | -$312.4M |
| Free cash flow | -$114.7M | -$290.5M | -$345.4M | -$350.3M |
| Total assets | $1.5B | $1.2B | $950.1M | $828.4M |
| Total liabilities | $1.8B | $1.6B | $1.9B | $1.4B |
| Stockholders' equity | -$284.5M | -$412.8M | -$932.5M | -$564.4M |
| Cash and investments | $172.4M | $51.4M | $11.2M | $66.4M |
| Total debt | $1.4B | $1.2B | $1.1B | $805.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 20, 2026 | Oct 20, 2026 |
| 6-K | Current report (foreign issuer) | Oct 14, 2026 | Oct 14, 2026 |
| 6-K | Current report (foreign issuer) | Oct 7, 2026 | Oct 6, 2026 |
| 6-K | Current report (foreign issuer) | Oct 5, 2026 | Oct 5, 2026 |
| 6-K | Current report (foreign issuer) | Aug 31, 2026 | Aug 31, 2026 |
| 6-K | Current report (foreign issuer) | Aug 21, 2026 | Aug 21, 2026 |
Source: SEC EDGAR filings. This is company-reported data, not investment advice.